Juvent Reveals Key Research Regarding Whole Body Vibration Therapy (WBV) Study Demonstrates That Juvent’s Technology Increases Bone Mineral Density in Osteopenic Girls
Palm Beach Gardens, F.L. (April 22, 2013) – Juvent’s Dynamic Motion Therapy® platform was found to be instrumental in increasing bone mineral density (BMD) in 2012 clinical trials conducted during a Chinese study of osteopenic girls with adolescent idiopathic scoliosis (AIS). The Florida-based medical technology company with a leading focus in bone health announced and discussed these key research findings regarding whole body vibration therapy (WBV) today. The symposium is sponsored by the National Osteoporosis Foundation, and the study was shared on the show floor in Chicago with healthcare professionals from around the US.
This randomized, controlled clinical trial and its results were published online on Sept. 26, 2012, by the Department of Orthopaedics and Traumatology, at the Chinese University of Hong Kong, Shatin, focused on osteopenic girls with adolescent idiopathic scoliosis (AIS). The effect of WBV on bone mass showed, in this study, that had a positive effect on improving absolute BMD (bone mineral density) at the femoral neck of the dominant leg and the lumbar spine BMC in these subjects studied.
The research showed that “the treatment group had numerically greater increases in all DXA parameters with a statistically significant difference being detected for the absolute and percentage increases in femoral neck BMD (bone mineral density) at the dominant leg (0.015 (SD=0.031)g/cm (2), 2.15 (SD+4.32)%) and the absolute increase in lumbar spine bone mineral content (1.17 (SD=2.05)g) in the treatment group.”
“We believe that this demonstrates the efficacy of the Juvent platform. Our entire approach to bone health is based on a unique, safe, whole body vibration therapy, also known as being in the class of a biophysical stimulatory technology,” pointed out Juvent’s CEO Rush Simonson. Juvent’s gentle vibrating platform, the patented Juvent 1000, offers a non-drug treatment, an exercise methodology, specifically designed for osteoporosis. The Juvent technology is based on 20 years of academic and clinical research, backed by more than 100 hundred published articles, and 34 in peer-reviewed journals. New research continues at St. Jude Children’s Hospital; Hebrew SeniorLife, affiliated with Harvard Medical School, and Children’s Hospital of Philadelphia.
Juvent has assembled an experienced management team of medical technology leaders, and experts bone health and anti-aging. Juvent’s 20 years of research and development, 20 plus patents and more than $20 million invested in the company’s vision, has resulted in groundbreaking research and technologies to combat the effects of aging and poor bone health. Their patented “Dynamic Motion Therapy®” device, first to meet OSHA guidelines, safely using only 0.3g and 32 to 37 Hz mechanical signals, and has proven to be effective for exercise. The patented “Smart Technology” automatically calibrates the treatment to each patient’s body weight and mass.
The Juvent 1000 is available now in the U.S. and Taiwan, and soon in Canada, Europe, Australia and New Zealand. In the U.S., the Juvent 1000 device is FDA cleared as a Class I medical device and the company plans to seek expanded FDA approval for additional bone therapies.